Innate Pharma SA
PAR:IPH
Innate Pharma SA
PAR:IPH
Price:
1.468
EUR
3.82%
Market Closed
Market Cap:
€137.6m
Relative Value
The Relative Value of one
IPH
stock under the Base Case scenario is
0.645
EUR.
Compared to the current market price of 1.468 EUR,
Innate Pharma SA
is
Overvalued by 56%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
IPH
Relative Value
Base Case
0.645
EUR
Overvaluation 56%
Multiples Across Competitors
IPH Competitors Multiples
Innate Pharma SA Competitors
Innate Pharma SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| FR |
|
Innate Pharma SA
PAR:IPH
|
135.3m EUR | 22.5 | -2.9 | -1.9 | -1.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
409.8B USD | 6.9 | 174.4 | 16.8 | 23.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.7B USD | 5.4 | 25.8 | 14.8 | 14.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
193.1B USD | 6.6 | 23.8 | 16.2 | 16.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.5B USD | 10.6 | 33.9 | 25 | 26.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
84.3B USD | 5.9 | 18.7 | 14.2 | 16.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
72.6B AUD | 3.2 | 16.8 | 11.5 | 14.4 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.1B EUR | 14.4 | 33.9 | 57.9 | 59.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
